Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sedana Medical AB ( (SE:SEDANA) ) has shared an update.
Sedana Medical reported first‑quarter 2026 net sales of SEK 53.4 million, down 7% year on year, though the gross margin held steady at 71% and the company achieved a positive Group EBITDA of SEK 1.8 million. EBITDA excluding the U.S. improved to SEK 5.1 million, net loss narrowed sharply to SEK 3.7 million, and the balance sheet remained solid with SEK 80.7 million in cash, signaling operational resilience despite weaker topline growth and ongoing U.S. registration investments weighing on cash flow.
More about Sedana Medical AB
Sedana Medical AB is a Stockholm‑based medtech and pharmaceutical company specializing in inhaled sedation for mechanically ventilated intensive care patients. The group’s core offering combines its Sedaconda ACD medical device with the Sedaconda (isoflurane) drug, positioning the company in the niche of ICU sedation solutions and listed on Nasdaq Stockholm since its founding in 2005.
Average Trading Volume: 174,507
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.03B
For a thorough assessment of SEDANA stock, go to TipRanks’ Stock Analysis page.